Back to search

Article

Ensartinib-Induced Organizing Pneumonia in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Rare Case Report

2024-09-01

Abstract excerpt

Ensartinib is a second-generation tyrosine kinase inhibitor (TKI) developed independently in China, which is superior to crizotinib in the treatment of anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC). In real-world investigations, no cases of organizing pneumonia (OP) have been reported among patients receiving enshatinib in NSCLC. Herein, we report a case of early OP in a 50-year-old...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
1ea0f4c2-309d-5f79-97ef-09c29efc2967
DOI
10.22541/au.172523092.22211584/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Ensartinib-Induced Organizing Pneumonia in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Rare Case ReportDOI 10.22541/au.172523092.22211584/v1
Osimertinib-induced severe bilateral pneumothorax: A case report.Semantic proximity
Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer.Semantic proximity
Successful administration of low-dose almonertinib in a patient with lung adenocarcinoma after osimertinib-induced interstitial lung disease: a case report and literature review.Semantic proximity
Adenovirus pneumonia mimicking osimertinib-induced pneumonitis in a patient with advanced NSCLC with EGFR mutation: A case report.Semantic proximity
Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC.Semantic proximity
Real-World Evaluation of Factors for Interstitial Lung Disease Incidence and Radiologic Characteristics in Patients With EGFR T790M-positive NSCLC Treated With Osimertinib in Japan.Semantic proximity
Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World Setting.Semantic proximity
Interstitial pneumonitis associated with EGFR/ ALK tyrosine kinase inhibitors used in non-small cell lung cancer: an observational, retrospective, pharmacovigilance study.Semantic proximity
Reduction of pericardial effusion in advanced non-small cell lung cancer patients with KRAS, TP53, and MET mutation treated with nivolumab.Semantic proximity
Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study.Semantic proximity
Organizing Pneumonia Phenotype.Semantic proximity
Organizing Pneumonia in a Patient following Treatment of Chronic Hepatitis B with Pegylated Interferon alfa-2b: A Case ReportSemantic proximity
Select a neighboring publication to make it the new centre.